Skip to main content
Journal cover image

First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status

Publication ,  Conference
Rizvi, NA; Shepherd, FA; Antonia, SJ; Brahmer, JR; Chow, LQ; Goldman, J; Juergens, R; Borghaei, H; Ready, NE; Gerber, DE; Shen, Y; Harbison, C ...
Published in: International Journal of Radiation Oncology*Biology*Physics
November 2014

Duke Scholars

Published In

International Journal of Radiation Oncology*Biology*Physics

DOI

ISSN

0360-3016

Publication Date

November 2014

Volume

90

Issue

5

Start / End Page

S31 / S31

Publisher

Elsevier BV

Related Subject Headings

  • Oncology & Carcinogenesis
  • 5105 Medical and biological physics
  • 3407 Theoretical and computational chemistry
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
  • 0299 Other Physical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rizvi, N. A., Shepherd, F. A., Antonia, S. J., Brahmer, J. R., Chow, L. Q., Goldman, J., … Gettinger, S. (2014). First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status. In International Journal of Radiation Oncology*Biology*Physics (Vol. 90, pp. S31–S31). Elsevier BV. https://doi.org/10.1016/j.ijrobp.2014.08.204
Rizvi, N. A., F. A. Shepherd, S. J. Antonia, J. R. Brahmer, L. Q. Chow, J. Goldman, R. Juergens, et al. “First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status.” In International Journal of Radiation Oncology*Biology*Physics, 90:S31–S31. Elsevier BV, 2014. https://doi.org/10.1016/j.ijrobp.2014.08.204.
Rizvi NA, Shepherd FA, Antonia SJ, Brahmer JR, Chow LQ, Goldman J, et al. First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status. In: International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2014. p. S31–S31.
Rizvi, N. A., et al. “First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status.” International Journal of Radiation Oncology*Biology*Physics, vol. 90, no. 5, Elsevier BV, 2014, pp. S31–S31. Crossref, doi:10.1016/j.ijrobp.2014.08.204.
Rizvi NA, Shepherd FA, Antonia SJ, Brahmer JR, Chow LQ, Goldman J, Juergens R, Borghaei H, Ready NE, Gerber DE, Shen Y, Harbison C, Chen AC, Gettinger S. First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2014. p. S31–S31.
Journal cover image

Published In

International Journal of Radiation Oncology*Biology*Physics

DOI

ISSN

0360-3016

Publication Date

November 2014

Volume

90

Issue

5

Start / End Page

S31 / S31

Publisher

Elsevier BV

Related Subject Headings

  • Oncology & Carcinogenesis
  • 5105 Medical and biological physics
  • 3407 Theoretical and computational chemistry
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
  • 0299 Other Physical Sciences